Financials data is unavailable for this security.
View more
Year on year Amphastar Pharmaceuticals Inc grew revenues 29.14% from 498.99m to 644.40m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 50.51% net income growth from 91.39m to 137.55m.
Gross margin | 52.98% |
---|---|
Net profit margin | 21.95% |
Operating margin | 29.61% |
Return on assets | 10.28% |
---|---|
Return on equity | 23.85% |
Return on investment | 11.88% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Amphastar Pharmaceuticals Inc fell by 11.80m. Cash Flow from Financing totalled 454.09m or 70.47% of revenues. In addition the company generated 183.50m in cash from operations while cash used for investing totalled 649.12m.
Cash flow per share | 4.02 |
---|---|
Price/Cash flow per share | 11.13 |
Book value per share | 15.04 |
---|---|
Tangible book value per share | 2.75 |
More ▼
Balance sheet in USDView more
Current ratio | 3.43 |
---|---|
Quick ratio | 2.61 |
Total debt/total equity | 0.82 |
---|---|
Total debt/total capital | 0.4506 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 17.33 |